Search clinical trials for: Nilotinib

Total 206 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Amgen

Active, not recruiting

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma | Pre B-Cell Acute Lymphoblastic Leukaemia

United States
University of Jena
Novartis Pharmaceuticals; Ludwig-Maximilians - University of Munich

Active, not recruiting

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Chronic Myeloid Leukemia

Germany
University of Jena

Completed

TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)

Chronic Myeloid Leukemia

Germany, Switzerland, Czechia
Novartis Pharmaceuticals

No longer available

Nilotinib, for Patients With CML-CP or CML-AP

Chronic Myelogenous Leukemia (CML)
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD (Nilo-cGVHD)

Chronic Graft Versus Host Disease

Israel, Italy
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Takeda

Completed

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Leukemia

United States
University of Michigan Rogel Cancer Center

Terminated

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States
UNC Lineberger Comprehensive Cancer Center

Completed

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous Leukemia

United States
Center for Primary Care and Public Health (Unisante)...
Centre Hospitalier Universitaire Vaudois

Completed

Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Cancer

Switzerland
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study (LAL1408)

Stem Cell Transplantation | Treatment

Italy
University Hospital, Bordeaux

Completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals

Completed

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chronic Myeloid Leukemia

Germany
Milton S. Hershey Medical Center

Terminated

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia, Chronic Phase

United States
Gustave Roussy, Cancer Campus, Grand Paris
Innovative Therapies For Children with Cancer Consortium

Terminated

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults (VINILO)

Refractory Low-grade Gliomas | Recurrent Low-grade Gliomas

Austria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults (VINILO)

Refractory Low-grade Gliomas | Recurrent Low-grade Gliomas

Austria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

Chronic Myeloid Leukemia

United States
Assiut University

Active, not recruiting

Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Patients Diagnosed as Chronic Meyloid Leukemia

Egypt
Organon and Co

Completed

MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

Rhinitis Allergic
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM)

Chronyc Myeloid Leukemia

Netherlands, Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase (CML0307)

Chronic Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase (CML0912)

Chronic Phase Philadelphia Positive | BCR-ABL Positive | Chronic Myeloid Leukaemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML0408)

Leukemia

Italy
Ariad Pharmaceuticals

Terminated

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (OPTIC-2L)

Chronic Phase Chronic Myeloid Leukemia

Belgium
Seoul National University Hospital

Completed

Effect of Nilotinib in Cerebellar Ataxia Patients

Ataxia, Cerebellar | Ataxia, Progressive

Korea, Republic of
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
Novartis Pharmaceuticals

Terminated

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib (MACS0254)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Novartis Pharmaceuticals

Completed

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (MACS0999)

Chronic Myelogenous Leukemia

United States, Canada
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway
Novartis Pharmaceuticals

Terminated

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations (MACS1148)

CML | Philadelphia Chromosome Positive (Ph+) | Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

United States
Novartis Pharmaceuticals

Completed

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

United States, France, Korea, Republic of, Thailand, Italy, Netherlands, Turkey, Hungary, Russian Federation, Spain, United Kingdom, Japan, Malaysia
University of Michigan Rogel Cancer Center

Withdrawn

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Leukemia, Chronic Myeloid

United States
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Chronic Phase Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, France, United Kingdom
Novartis Pharmaceuticals

Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Germany, Canada, France, Spain, Italy
Novartis Pharmaceuticals

Completed

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Chronic Myeloid Leukemia

United Kingdom, Germany
Novartis Pharmaceuticals

Completed

Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers

Healthy
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
Hyewon Chung

Completed

A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin

Healthy

Korea, Republic of
University Health Network, Toronto
Novartis

Completed

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Chronic Phase Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blastic Phase Chronic Myeloid Leukemia | Resistant to Tyrosine Kinase Inhibitor Therapy

Canada
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Novartis Pharmaceuticals

Completed

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Chronic Myelogenous Leukemia

Turkey
Goethe University

Completed

Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia

Spain, Germany, France

Search clinical trials for: Nilotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations